已上市MEK抑制剂合成路线综述  

Review of Synthetic Routes of Marketed MEK Inhibitors

作　　者：李瑞鹏 赵建宏[1] 夏广新[2] 谢建树[2] 邓卫平[1] LI Ruipeng;ZHAO Jianhong;XIA Guangxin;XIE Jianshu;DENG Weiping(School of Pharmacy,East China University of Science and Technology,Shanghai 200237;Central Research Institute,Shanghai Pharmaceutical Holding Co.,Ltd.,Shanghai 201203)

机构地区：[1]华东理工大学药学院,上海2002372 [2]上海医药集团股份有限公司中央研究院,上海201203

出　　处：《中国医药工业杂志》2021年第10期1278-1290,共13页Chinese Journal of Pharmaceuticals

摘　　要：丝裂原活化的细胞外信号调节激酶(MEK)抑制剂是重要的抗肿瘤药物,目前已上市4个产品,分别是曲美替尼、考比替尼、司美替尼和比美替尼。本文简要介绍了这4种药物,并对已报道的合成路线进行综述。Mitogen-activated extracellular signal-regulated kinase(MEK)inhibitors are important antineoplastics.At present,four drugs have been marketed,namely trametinib,cobimetinib,selumetinib and binimetinib.This paper briefly introduces these drugs and reviews their reported synthetic routes.

关 键 词：抗肿瘤药 丝裂原活化的细胞外信号调节激酶(MEK) 抑制剂 曲美替尼 考比替尼 司美替尼 比美替尼 合成 

分 类 号：R944.4[医药卫生—药剂学]